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We compared our findings to other studies reported in
Europe or Canada to identify regional differences in predis-
posing factors, treatment strategies, and outcome of these
patients.
Methods
We retrospectively analyzed children with cerebral venous
thrombosis from 5 centers in the United States, University
of Texas Southwestern Medical Center, Dallas, Texas; 19
patients, State University of New York at Buffalo, New York;
16 patients, Metro Health Medical Center, Cleveland, Ohio;
8 patients, University of Michigan, Ann Arbor, Michigan; 13
patients, Vanderbilt University, Nashville, Tennessee; 14
patients) from 1992 to 2001. All patients had radiographic
confirmation of cerebral venous thrombosis by cranial ultra-
sound, computerized tomography (CT) scan, or magnetic
resonance imaging (MRI). Diagnosis of cerebral venous
thrombosis was established by MRI and magnetic resonance
venography (MRV) in 55 patients, Cranial CT and cerebral
angiography in 2 patients, and CT head and cranial ultra-
sound in 13 patients. These 13 patients were all neonates.
Cerebral venous thrombosis in children is rare, withan incidence less than 1 per 100 000 children peryear.1 However, venous thromboses are increasingly
recognized in children due to advances in imaging. Most
published papers related to pediatric or neonatal cerebral
venous thrombosis are reported from Europe, Canada, and
other countries.1-9 Cases reported from the United States are
typically single-center series or case reports (see Table 1).10-14
This study was done to analyze clinical and imaging fea-
tures, risk factors, treatment options, and outcome of cere-
bral venous thrombosis in children at various US centers.
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Children younger than 12 years of age were included.
Children younger than 1 month of age were classified as
neonates. Some of the patients were identified because one of
the authors was involved in these children’s care, and others
were identified by searching for the appropriate International
Classification of Diseases, Ninth Revision (ICD-9) codes at the
medical records departments of participating centers. Data
were collected on a standardized data collection form. Data
was analyzed using SPSS 13.0. Logistic regression analysis
was performed to identify predictors of outcome.
Table 1. Comparison of Published Studies Related to Pediatric and Neonatal Cerebral Venous Thrombosis
Number of Complete
Author Country Patients Predisposing Factor Clinical Labs Location ICH Recovery Mortality
Byers and Hass United States 50 Infections 53% SSS 24% 25%
(1933)10 TS 19%
Deep veins 19%
Shevell et al 
(1989)2 Canada 17 Perinatal complications Seizures 90% 58%
neonates 25%
Barron et al United States 25 Hypercoaguable state Seizures 45% 75% 4%
(1992)11 25%
Sepsis/dehydration 25% Headache 34%
Lee et al (1995)3 Taiwan 25 Seizures 100% 50% 8%
Headache 37%
Carvalho et al United States 31 Mastoiditis 30% 25% 35% 6%
(2001)12 Cardiac malformation 
27%
Dehydration 21%
Huisman et al Switzerland 19 Trauma 50%
(2001)4 Infection 35%
Coagulation defects 15%
deVeber et al Canada 160 Prothrombotic state 32% Seizures 58% Anemia SSST 55% 43% 48% 8%
(2001)1 Dehydration 25% Headache 34% TS 51%
Perinatal complications Hemiparesis 13% Deep cerebral 
24% Papilledema 12% venous 
Infections 18% thrombosis 
38%
Wu et al United States 30 Extracorporeal Seizures 57% Genetic 50%
(2002)13 neonates membrane 12% IVH
oxygenation 29% 33%
Heart malformation 23%
Heller et al Germany 149 Prothrombotic state 56% Headache 32% Lipoprotein SSS 62%
(2003)5 Infections 29% Seizures 38% a 41% TS 14%
Motor 3% Genetic 18% Sigmoid 7%
Barnes et al Australia 16 Infections 88% Headache 45%
(2004)6 Seizures 25%
Motor 6%
Kenet et al Israel 46 Infections 47% AplA 10% 4%
(2004)7 Prothrombotic state Genetic 20%
38%
Sebire et al Europe 42 Mastoiditis 47% Seizures 40% Anemia 55% SSST 40%% 28% 26% 12%
(2005)8 Other infections 24% Headache 68% High factor TS 48%
Dehydration 21% Hemiparesis 33% VIII 54% Sigmoid 26%
Prothrombotic state 16% Deep cerebral
Recent surgery 9% venous 
thrombosis 
20%
Bonduel et al Argentina 38 Prothrombotic 34% None
(2006)9
Fitzgerald et al United States 42 Dehydration 26% Seizures 57% Genetic 27% SSST 67%
(2006)14 neonates Cardiac malformation Respiratory 19% TS 55%
26% Apnea 19% Sigmoid 14%
Infections 17% Poor feeding 12% Deep cerebral 52% 12% 2%
venous IVH 
thrombosis 20%
45%
NOTE: Apl A = Anti phospholipid antibody; SSS = superior sagittal sinus; TS = transverse sinus; SSST = superior sagittal sinus thrombosis; ICH = intracerebral
hemorrhage; IVH = intraventricular hemorrhage.
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Results
Seventy-nine charts were reviewed, and 9 individuals
were excluded due to lack of imaging confirmation of a
cerebral venous thrombosis or because of other incom-
plete information. Of the 70 children who were included,
25 (35%) were neonates, and 38 (55%) were younger than
6 months of age. The age range was 6 days to 12 years,
and 28 (40%) were male. The male-to-female ratio was
1:1.5 for both neonates and nonneonates.
Clinical features at presentation (Table 2) included
seizures (59%), fever (33%), coma (30%), drowsiness
(21%), motor weakness (21%), and headache (18%).
Headache was present in 12 of 25 patients (45%) ages 6 
to 12 years. Common neurological abnormalities (Table 3)
included decreased level of consciousness (50%), papilledema
(18%), cranial nerve palsy (33%), hemiparesis (29%), and, in
neonates, hypotonia (22%).
Predisposing factors were identified in 63 (90%) children.
These included infection (otitis, mastoiditis, meningitis, and
sepsis) in 40%, perinatal complications (hypoxic-ischemic
injury, birth trauma) in 25%, hypercoagulable/hematological
diseases (eg, protein C or S deficiency, systemic lupus erythe-
matosus, and homocystinuria) in 13%, and various other con-
ditions (eg, nephrotic syndrome, cancer, chemotherapy,
dehydration) in 10%. However, testing for a hypercoagulable
state was only performed in 39 patients (55%). This workup
was not standardized and differed from one center to another.
Only 16% patients had multiple predisposing factors 
(Table 4).
Most children (79%) had at least 2 diagnostic studies (cra-
nial ultrasound, CT, MRI) for confirmation. Ultrasound was
done only in neonates, and cerebral venous thrombosis was
confirmed by CT or MRI in all patients where ultrasound
suggested a diagnosis of cerebral venous thrombosis.
Hemorrhagic infracts were present in 40% of patients, and
hydrocephalus was present in 10% of patients. Five patients
underwent cerebral venography (Table 5).
Transverse sinus thrombosis was more common (73%)
than sagittal sinus thrombosis (35%). The superficial and
deep venous system was involved in 10 (15%) children,
and multiple sinuses were involved in more than 70% of
patients (Table 6).
Three patients (5%) were treated with direct thromboly-
sis with urokinase, 15 (20%) patients received anticoagula-
tion with unfractionated heparin or low molecular weight
heparin, 49 (70%) patients were treated with antibiotics and
hydration, and 7 patients (10%) underwent surgery (decom-
pression and/or shunt placement). These patients were not
randomized, and treatment was based entirely on the clini-
cal situation. Nine patients were discharged on warfarin,
and 22 patients were discharged on aspirin.
Nine (13%) patients died, including 6 neonates (25%)
and 3 other children (7%). One patient who underwent
thrombolysis died, 1 died in the anticoagulation treatment
group, and 7 children in the antibiotic/hydration group died.
Table 2. Clinical Presentations, n (%)
Seizures 41 (59) 20 neonates, 21 others
Focal 26 (37)
Generalized 15 (21)
Coma 21 (30)
Drowsy/stuporous 37 (51)
Headache 12 (18)
Generalized weakness 20 (29)
Focal weakness (hemi/monoparesis) 16 (21)
Jitteriness (neonates) 12 (18)
Agitation/behavioral symptoms 6 (10)
Fever 23 (33)
Table 3. Neurological Findings, n (%)
Decreased level of consciousness 37 (50)
Papilledema 12 (18)
Cranial nerve palsy 23 (34)
Dysarthria 9 (13)
Hemiparesis 20 (29)
Aphasia 3 (5)
Monoparesis 3 (5)
Ataxia 6 (9)
Hypotonia (neonates) 16 (22)
Neck stiffness 3 (5)
Ear infection 10 (15)
Table 4. Predisposing Factors, n (%)
Identified 63 (90)
Not identified 7 (10)
Infection 28 (40)
Otitis/mastoiditis/sinusitis 17 (25)
Meningitis 2 (3)
Sepsis 9 (12)
Perinatal complications 18 (25)
Hypoxic ischemic encephalopathy 16 (22)
Birth trauma 2 (3)
Hypercoagulable/hematological 13 (20)
Protein C deficiency 1
Protein S deficiency 2
Anti-thrombin-III deficiency 1
Lupus anticoagulant 2
Factor V mutation 1
Homocystinuria 3
Disseminated intravascular coagulation 1
Thrombotic thrombocytopenic purpura 1
Sickle cell disease 1
Other conditions 17 (25)
Nephrotic syndrome 1
Systemic lupus erythematosis 2
Cancer (lymphoma, leukemia) 2
Cancer chemotherapy 1
Severe dehydration 3
Oral contraceptives 1
Anemia 7
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The outcome was assessed at discharge: 29 (41%) patients
were normal, and 32 patients (46%) had a neurological deficit
at discharge. Thirty-day outcome or a longer follow-up was
not available due to the retrospective nature of study.
Univariate analysis revealed that predictors of mortality were
coma at presentation, age less than 1 month of age, presence
of intracerebral hemorrhage, and seizures. On multivariate
analysis, the best predictors of mortality were coma at pres-
entation (odds ratio 3.9 [95% confidence interval (CI): 0.0-
7.6]) and seizures (odds ratio 2.1 [95% CI: 0.8-5.5]).
Discussion
Although cerebral venous thrombosis is uncommon in
children, it occurs more often during the first 6 months
of life. In our series, 55% of the children belonged to this
age group. Similarly, 54% of the children in the Canadian
cerebral venous thrombosis registry were younger than 1
year old.1 Why children in this age group are more sus-
ceptible to cerebral venous thrombosis than older chil-
dren is not clear. Previous reports have suggested the
presence of multiple risk factors as the potential cause of
cerebral venous thrombosis in neonates.13 Reported risk
factors contributing to cerebral venous thrombosis in
infants and neonates include dehydration, infections,
extracorporeal membrane oxygenation treatment, and a
variety of maternal factors.5,7,8,13 At least 1 risk factor was
identified in 90% of patients in our series, comparable to
published reports from European and Canadian studies.
The frequency of prothrombotic states would no doubt
have been higher in our series had a uniform procedure
for their evaluation been in place. Prothrombotic factors
are increasingly recognized as a cause of cerebral venous
thrombosis in pediatric patients as in adults.15,16 Anemia,
lipoprotein a, and high factor VIII have been suggested as
predisposing factors for pediatric cerebral venous throm-
bosis.1,5,8,17 The role of these factors in adult cerebral
venous thrombosis has not been established.
Contrary to some previous studies reporting male predom-
inance, our patient population was predominantly female.18
Most of the large series dealing with adult patients with cere-
bral venous thrombosis reported female predominance.19
Clinical features in neonatal and nonneonatal cerebral
venous thrombosis vary, but seizures remain the most com-
mon presentation in both groups. Hypotonia and irritability
were more common in neonates, whereas headache and
motor symptoms predominated in the nonneonatal group.
These symptoms are nonspecific, and diagnosis of cerebral
venous thrombosis is challenging in these patients. A low
threshold for neuroimaging is required for early diagnosis.
Cranial ultrasound may be helpful in neonatal cerebral
venous thrombosis, but its findings often need to be con-
firmed by MRI and magnetic resonance venography.20,21
Treatment of pediatric cerebral venous thrombosis is
controversial. Treatment of cerebral venous thrombosis was
more aggressive in our patients than in previous reports.
Three patients (previously reported) were treated with
thrombolytic therapy,22 and 7 patients underwent surgical
decompression and shunt placement. Experience with
thrombolytic therapy in pediatric cerebral venous thrombo-
sis is limited to a few case reports.23-25 Griesmer et al23
reported a 10-year-old boy with superior sagittal sinus
thrombosis, transverse sinus thrombosis, straight sinus, and
sigmoid sinus thrombosis. Due to progressive neurological
deterioration, he was treated with local urokinase throm-
bolysis and improved dramatically. Wong et al24 reported a
1-day-old neonate with parasagittal hemorrhage due to cor-
tical vein thrombosis. This baby recovered completely after
locally applied urokinase. Gebara et al25 reported a 9-week-
old girl with dural sinus thrombosis secondary to subclavian
vein catheterization. She had complete recovery after local
Table 5. Neuroimaging Findings
Cranial ultrasound 18/25 neonates
Abnormal 10
Sinus thrombosis alone 2
Hemorrhage 5
Sinus thrombosis + hemorrhage 3
Head CT scan: Done 43/70 (neonates, 18; 
children, 25)
Normal 8
Thrombosed sinus 11
Hemorrhage 15
Infarct 6
Hydrocephalus 3
Brain MRI/MRV: Done 55/70 (neonates, 10; 
children, 45)
Thrombosed sinus 54
Hemorrhage 23
Infarct 10
Hydrocephalus 3
Cerebral angiogram: Done 5/70
Sinus thrombosis 5
Hemorrhagic infarct on CT or MRI 28 (40%)
NOTE: CT = computed tomography; MRI = magnetic resonance imaging; 
MRV = magnetic resonance venography.
Table 6. Location of Thrombosis, n (%)
SSS 7 (10)
TS alone 8 (12)
SS alone 0
Sigmoid sinus 0
JV 0
Internal cerebral vein/vein of Galen 2 (3)
Cortical vein 2 (3)
SSST + TS 16 (24)
TS + sigmoid sinus 9 (13)
TS + SS + JV 7 (10)
Bilateral TS 13 (18)
Superficial + deep venous system 6 (9)
NOTE: SSS = superior sagittal sinus; TS = transverse sinus; SS = straight sinus;
JV = jugular vein; SSST = superior sagittal sinus thrombosis.
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urokinase thrombolysis. One study compared direct throm-
bolysis to heparin therapy for treatment of adult cerebral
venous thrombosis in a nonrandomized manner and showed
that thrombolysis was both safe and effective in comparison
to anticoagulation with heparin.26 Despite its effectiveness
in achieving recanalization or patency of thrombosed
intracranial sinuses, safety and availability are the main lim-
itations of thrombolysis.27
The evidence regarding anticoagulation in adult cerebral
venous thrombosis is conflicting. Many reports suggest its
safety and efficacy in patients with puerperal cerebral venous
thrombosis and in patients with intracerebral hemorrhage
and hemorrhagic infarction.28-30 The most recent random-
ized, placebo-controlled trial of anticoagulant treatment with
low molecular weight heparin for cerebral sinus thrombosis
failed to show a significant benefit.31 Despite this fact, anti-
coagulation remains the mainstay of treating adult cerebral
venous thrombosis. There are no randomized trials related to
anticoagulation in pediatric cerebral venous thrombosis.
Anticoagulation with heparin, low molecular weight heparin,
and warfarin is reported to be safe in pediatric patients with
cerebral venous thrombosis.32,33 The use of anticoagulants
was less common in our patients (20%) as compared to 34%
to 70% in other reports.1,32,33 Anticoagulation is used less
commonly in neonates than in older children.1,14 Most of
these patients are treated with hydration and antibiotics.
Surgical treatment of cerebral venous thrombosis is gener-
ally reserved for intracerebral hematomas with mass effect
and for hydrocephalus. Seven patients underwent surgery,
one of whom was a neonate. A more conservative approach
in neonatal cerebral venous thrombosis is applied.
The mortality was high in our series, especially among
neonates, although the prognostic indicators were similar in
our series to those in previous reports.1 Our findings add to
the current state of knowledge related to pediatric cerebral
venous thrombosis, but our data are subject to the same
limitations as other retrospective studies. There is a chance
that cases have been missed during the coding process. An
evaluation for hypercoagulable states was not done at some
centers and varied from one center to another. All partici-
pating centers, being tertiary care centers, tend to care for
sicker patients, perhaps explaining the high mortality. 
We think that these 70 patients from 5 US centers only
present a fraction of pediatric cerebral venous thrombosis.
Retrospective reviews based on the ICD coding system may
miss a number of patients. A recent study pointed out that
coding accuracy ranges from 37% to 88% for acute ischemic
stroke.34 The North American pediatric stroke registry and
some of the European pediatric stroke registries have made
an extraordinary contribution in the understanding of pedi-
atric stroke, especially pediatric cerebral venous thrombosis.
A large, prospective, global, multinational registry for pedi-
atric patients with cerebral venous thrombosis is warranted
to understand the entity and plan intervention for managing
this condition. Large, multicenter, online registries are fea-
sible due to advances in information technology and inter-
national collaboration. These may be helpful in identifying
regional differences in cerebral venous thrombosis and as
well as enrolling patients for future randomized trials.35
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